Alexander J. Thompson
Elite in Hepatitis B

Alexander J. Thompson

St Vincent's Hospital Melbourne
Melbourne, VIC, AU 
Elite in Hepatitis B
St Vincent's Hospital Melbourne
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Alexander Thompson practices in Melbourne, Australia. Mr. Thompson is rated as an Elite expert by MediFind in the treatment of Hepatitis B. His top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 233 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 53 articles and participated in 1 clinical trial in the study of Hepatitis B.

Gender
Male

Locations

St Vincent's Hospital Melbourne
Melbourne, VIC, Australia
Other Locations
627 Rode Road, Chermside, QLD 4032, Australia
Grattan Street, Parkville, VIC 3010, Australia
Level 1, Hospital Avenue, Nedlands, WA 6009, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients
A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital: a Randomised Trial
The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital: a Randomised Trial
Enrollment Status: Completed
Publish Date: May 24, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

233 Total Publications

Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignancies.
Response to Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignancies.
Journal: Haematologica
Published: August 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thompson's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile